checkAd

     201  0 Kommentare Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

    The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023 / RELIEF THERAPEUTICS Holding SA …

    The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™

    GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief Therapeutics"), a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with rare diseases, today announced the Company will present the results of pre-clinical research evaluating the metabolic impact of PKU GOLIKE® on nitrogen balance, muscle strength and glucose. The data will be presented in a poster session at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, March 18-21, 2023. The Company will also have an exhibit in booth #109 at the meeting.

    People living with PKU do not have the ability to metabolize the amino acid phenylalanine (Phe) found in many foods and they require supplementation of amino acid-based foods for special medical purposes (FSMPs) to prevent protein deficiency and optimize metabolic control. These protein substitutes are typically characterized by altered kinetic profiles compared to that of a slowly absorbed and digested intact protein. The rate of amino acid absorption affects the post-prandial utilization of dietary nitrogen, and the prolonged release of amino acids could support anabolic requirements. Developed with Relief Therapeutics' proprietary, patent-protected Physiomimic Technology™ platform, PKU GOLIKE is the first prolonged-release, amino acid FSMP, characterized by a special coating that enables physiological absorption of the amino acids mirroring that of natural proteins.

    "The results from this pre-clinical research demonstrate the important body composition benefits of the physiological absorption of our prolonged-release amino acid supplement PKU GOLIKE1," said Nermeen Varawalla, M.D., Ph.D., chief medical officer at Relief Therapeutics. "The findings provide direction for our forthcoming clinical research to confirm the metabolic benefits of PKU GOLIKE, assessing body composition and oxidative stress in active PKU patients, thereby substantiating our completed pre-clinical work."

    Seite 1 von 4



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023 / RELIEF THERAPEUTICS Holding SA …